The interaction patterns of combined antibacterial agents. Experiments with two agardiffusion methods.
D000667:Ampicillin / Q000494:pharmacology*; D002701:Chloramphenicol / Q000494:pharmacology*; D003091:Colistin / Q000494:pharmacology*; D004336:Drug Antagonism; D004357:Drug Synergism; D004755:Enterobacteriaceae / Q000187:drug effects*; D004917:Erythromycin / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects*; D005672:Fusidic Acid / Q000494:pharmacology*; D007612:Kanamycin / Q000494:pharmacology*; D007709:Klebsiella / Q000187:drug effects*; D008712:Methicillin / Q000494:pharmacology*; D009268:Nalidixic Acid / Q000494:pharmacology*; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology*; D011511:Proteus / Q000187:drug effects*; D011550:Pseudomonas aeruginosa / Q000187:drug effects; D012293:Rifampin / Q000494:pharmacology*; D012475:Salmonella / Q000187:drug effects*; D013210:Staphylococcus / Q000187:drug effects*; D013291:Streptococcus / Q000187:drug effects*; D013307:Streptomycin / Q000494:pharmacology*; D013752:Tetracycline / Q000494:pharmacology*
D010406:Penicillins; D009268:Nalidixic Acid; D007612:Kanamycin; D005672:Fusidic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D000667:Ampicillin; D013752:Tetracycline; D008712:Methicillin; D012293:Rifampin; D013307:Streptomycin; D003091:Colistin